Institutional members access full text with Ovid®

Thalidomide Therapy for Aggressive Histiocytic Lesions in the Pediatric Population

Bailey, Kelly M. MD, PhD; Castle, Valerie P. MD; Hummel, Jennifer M. MD; Piert, Morand MD; Moyer, Judith RN, PNNP; McAllister-Lucas, Linda M. MD, PhD

Journal of Pediatric Hematology/Oncology: August 2012 - Volume 34 - Issue 6 - p 480–483
doi: 10.1097/MPH.0b013e3182580d6e
Clinical and Laboratory Observations

Aggressive histiocytic lesions are uncommon in the pediatric population. These neoplasms occur in isolation or after therapy for other types of hematopoietic malignancy such as T-cell acute lymphoblastic leukemia. The etiology of these lesions is poorly understood, and no definitive standard of care has been established for patients with these diagnoses. Here, we report the success of thalidomide treatment for 2 subtypes of histiocytic proliferation—metastatic histiocytic sarcoma and extracutaneous juvenile xanthogranuloma—in pediatric patients. Our findings highlight the importance of considering thalidomide therapy in this unique and difficult to treat patient population.

Departments of *Pediatrics and Communicable Diseases, University of Michigan Medical School

§Radiology, Division of Nuclear Medicine, University Hospital

Pathology, University of Michigan, Ann Arbor, MI

Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA

L.M.M.L. is supported by the Shirley K. Schlafer Foundation.

The authors declare no conflict of interest.

Reprints: Linda McAllister-Lucas, MD, PhD, University of Michigan Medical Center, 3520 MSRB1, 1150 West Medical Center Drive, Ann Arbor, MI 48109 (e-mail: lindaluc@umich.edu).

Received January 12, 2012

Accepted March 29, 2012

Copyright © 2012 Wolters Kluwer Health, Inc. All rights reserved.